secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0001193125-23-081417
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo reports positive Phase 2 results for ANEB-001 reversing THC effects
---------------------------------------------------------------------------

- Low 10 mg dose of ANEB-001 given 1 hour after THC rapidly reversed psychotropic effects (VAS feeling high p<0.0001).
- Pre-specified pooled analysis at 21/30 mg THC showed significance on all primary outcomes (p<0.02 for each).
- ANEB-001 was well tolerated; no serious adverse events; mild to moderate THC symptoms observed before dosing.
- High-fat meal blunted THC effects, but 10 mg ANEB-001 still significantly reduced VAS feeling high (p=0.003).
- Company expects End of Phase 2A meeting with FDA by mid-2023 to discuss path forward.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000119312523081417/0001193125-23-081417-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000119312523081417/d483501d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-081417

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer